Armenia Approves Agenus’ Botensilimab and Balstilimab for Metastatic Colorectal Cancer
Agenus said Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab) for use together in adults with previously treated microsatellite-stable metastatic colorectal cancer. The company described the approvals as the first for this combination in Armenia.
Agenus said Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab). The two medicines are approved for combined use in adults with previously treated microsatellite-stable metastatic colorectal cancer.
The company described the decision as Armenia’s first approval for this combination. Agenus is a Nasdaq-listed immuno-oncology company based in Lexington, Massachusetts. Its announcement identified botensilimab as BOT and balstilimab as BAL.
For patients in Armenia with previously treated microsatellite-stable metastatic colorectal cancer, this authorization may broaden the conversation about available immunotherapy options. Clinicians and families could weigh potential benefits against tolerability, cost, and access, while regulators and payers may consider how the combination fits local care pathways. Because the announcement offers limited real-world or local data, its practical effect on survival, quality of life, and health-system resources remains uncertain and would likely depend on implementation, uptake, and post-marketing evidence.